Spatiotemporal analysis of TDP-43 toxicity and endolysosomal turnover mechanisms
TDP-43毒性和内溶酶体周转机制的时空分析
基本信息
- 批准号:10626673
- 负责人:
- 金额:$ 39.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:ALS patientsAcuteAffectAlzheimer&aposs DiseaseAmyotrophic Lateral SclerosisBiological AssayCellsCessation of lifeCharacteristicsChemicalsChronicComplexDNADataDefectDegradation PathwayDevelopmentDiagnosisDiseaseDot ImmunoblottingEpitopesEventExhibitsFrontotemporal DementiaGene ExpressionGenesGeneticGenetic ScreeningGenome engineeringGoalsGrantHomeostasisHumanIn SituInclusion Body MyositisLabelLeadLife ExpectancyLinkMapsMeasurementMediatingMembraneMessenger RNAModelingMolecular ChaperonesMonitorMotor NeuronsMutationNatureNerve DegenerationNeurodegenerative DisordersNeuronsNuclearNuclear ExportNuclear RNAOpticsParalysedPathogenesisPathologicPathologyPathway interactionsPatientsPhenotypePhysiologic pulsePhysiologicalProsencephalonProteinsQuality of lifeRNARNA SplicingRNA metabolismRNA-Binding ProteinsReporterRoleSolubilitySorting - Cell MovementSupporting CellSystemTDP-43 aggregationTestingTherapeuticTimeToxic effectTranslationsUbiquitinationYeastsbasedrug candidateeffective therapyfrontotemporal lobar dementia-amyotrophic lateral sclerosisfused in sarcomagain of functioninnovationinsightlimbic-predominant age-related TDP-43 encephalopathyloss of functionmotor neuron degenerationneuron lossneuronal survivalnew therapeutic targetnovelnovel strategiesnovel therapeutic interventionnucleocytoplasmic transportoptogeneticsprotein TDP-43protein metabolismproteostasisresponseribosome profilingsmall moleculespatiotemporalstress granuletargeted treatmenttherapy developmenttooltranscriptome sequencingubiquitin-protein ligaseyeast genetics
项目摘要
Amyotrophic Lateral Sclerosis (ALS) is a devastating disease in which progressive degeneration of motor
neurons leads to paralysis, usually resulting in death 2-5 years after diagnosis. No therapies exist that
significantly increase quality of life or life expectancy. Mutations in >30 genes are linked to ALS onset, albeit
>90% of all ALS cases are sporadic. However, a unifying cellular hallmark in >95% of all ALS cases is the
cytoplasmic mis-localization, accumulation, and aggregation of the nuclear RNA binding protein TDP-43 (TAR
DNA/RNA binding protein 43) in motor neurons and support cells. Similar TDP-43 pathology is observed in other
neurodegenerative diseases, including in forebrain neurons of ~50% of Frontotemporal dementia patients (FTD).
TDP-43 pathology confers a toxicity to neurons, but the nature of this toxicity remains fiercely debated. Loss of
nuclear function (LOF) and gain of cytoplasmic function (GOF) mechanisms have been proposed, though
separating such mechanisms and identifying the earliest impacts of TDP-43 pathology has remained elusive.
Regardless, a therapeutic strategy that has shown promise in some ALS models is promoting the degradation
of cytoplasmic TDP-43. Recently, cytoplasmic TDP-43 was shown to be degraded via a novel endolysosomal
pathway, which, when induced, suppresses TDP-43 toxicity. However, understanding of this degradation
pathway remains limited. Key gaps in understanding include determining, in an ALS-relevant neuronal model,
the earliest and most disease-relevant impacts of TDP-43 pathology and defining how endolysosomal TDP-43
degradation occurs. The aims of this grant are: 1.) Establish a novel endogenous TDP-43 reporter system in
neurons that allows precise control of TDP-43 abundance and cellular localization via small molecule and
optogenetic means. Using this system, the impacts of altered TDP-43 levels and localization on TDP-43 itself,
ALS phenotypes and gene expression, focusing on RNA abundance and translation, will be examined. 2.) Test
an endolysosomal degradation model involving TDP-43 ubiquitination and endosomal membrane invagination
in neurons using an optical pulse labelling approach. TDP-43 degradation mechanisms will also be defined in
patient-derived ALS models using similar means. Finally, a novel high throughput yeast dot-blot assay will be
used to identify genetic and chemical regulators of TDP-43 and Fused in Sarcoma (FUS) abundance, which is
also implicated in ALS and FTD pathology. This grant is innovative in that a novel approach to exert
spatiotemporal control of TDP-43 expression, which promises separation of TDP43 LOF and GOF toxicity
effects, and a means to identify regulators of TDP-43 and FUS abundance via dot blot, are proposed. Finally,
mechanistically defining endolysosomal-based means of cytoplasmic TDP-43 degradation promises new basic
insight into proteostasis for TDP-43 and other substrates. In summary, TDP-43 and FUS are logical entry points
for the study of ALS and FTD. This grant will enhance disease understanding and may lead to identification of
new therapeutic targets with broad patient applicability.
肌萎缩侧索硬化症 (ALS) 是一种破坏性疾病,患者运动神经进行性退化
神经元导致瘫痪,通常导致诊断后 2-5 年内死亡。不存在任何治疗方法
显着提高生活质量或预期寿命。尽管超过 30 个基因的突变与 ALS 发病有关
>90% 的 ALS 病例是散发的。然而,超过 95% 的 ALS 病例的一个统一的细胞特征是
核 RNA 结合蛋白 TDP-43 (TAR
运动神经元和支持细胞中的 DNA/RNA 结合蛋白 43)。在其他疾病中也观察到类似的 TDP-43 病理学
神经退行性疾病,包括约 50% 额颞叶痴呆患者 (FTD) 的前脑神经元。
TDP-43 病理学赋予神经元毒性,但这种毒性的性质仍然存在激烈争论。损失
尽管已经提出了核功能(LOF)和细胞质功能获得(GOF)机制
分离这些机制并确定 TDP-43 病理学的最早影响仍然难以捉摸。
无论如何,在某些 ALS 模型中显示出希望的治疗策略正在促进降解
细胞质TDP-43。最近,细胞质 TDP-43 被证明可通过一种新型内溶酶体降解
途径,当被诱导时,抑制 TDP-43 毒性。然而,对这种退化的理解
途径仍然有限。理解方面的主要差距包括在 ALS 相关神经元模型中确定,
TDP-43 病理学的最早和最相关的影响以及定义内溶酶体 TDP-43
发生降解。这笔赠款的目的是: 1.) 建立一种新型内源性 TDP-43 报告系统
神经元可以通过小分子精确控制 TDP-43 丰度和细胞定位
光遗传学手段。使用该系统,改变 TDP-43 水平和定位对 TDP-43 本身的影响,
将检查 ALS 表型和基因表达,重点是 RNA 丰度和翻译。 2.) 测试
涉及 TDP-43 泛素化和内体膜内陷的内溶酶体降解模型
使用光脉冲标记方法在神经元中进行标记。 TDP-43 降解机制也将在
使用类似方法衍生的患者 ALS 模型。最后,一种新型的高通量酵母斑点印迹测定将是
用于鉴定 TDP-43 和肉瘤融合 (FUS) 丰度的遗传和化学调节因子,
也与 ALS 和 FTD 病理有关。这笔赠款的创新之处在于,它采用了一种新颖的方法来发挥作用
TDP-43 表达的时空控制,有望分离 TDP43 LOF 和 GOF 毒性
提出了一种通过斑点印迹识别 TDP-43 和 FUS 丰度调节因子的方法。最后,
机械地定义基于内溶酶体的细胞质 TDP-43 降解方法有望提供新的基础
深入了解 TDP-43 和其他底物的蛋白质稳态。综上所述,TDP-43和FUS是逻辑切入点
用于 ALS 和 FTD 的研究。这笔赠款将增进对疾病的了解,并可能导致识别
具有广泛患者适用性的新治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sami Barmada其他文献
Sami Barmada的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sami Barmada', 18)}}的其他基金
Atypical TDP43 isoforrms driving neurodegeneration in FTD/ALS
非典型 TDP43 亚型导致 FTD/ALS 神经退行性变
- 批准号:
10295762 - 财政年份:2019
- 资助金额:
$ 39.3万 - 项目类别:
Atypical TDP43 isoforrms driving neurodegeneration in FTD/ALS
非典型 TDP43 亚型导致 FTD/ALS 神经退行性变
- 批准号:
10057282 - 财政年份:2019
- 资助金额:
$ 39.3万 - 项目类别:
Atypical TDP43 isoforrms driving neurodegeneration in FTD/ALS
非典型 TDP43 亚型导致 FTD/ALS 神经退行性变
- 批准号:
10534172 - 财政年份:2019
- 资助金额:
$ 39.3万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
10619646 - 财政年份:2016
- 资助金额:
$ 39.3万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
9973175 - 财政年份:2016
- 资助金额:
$ 39.3万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
9324055 - 财政年份:2016
- 资助金额:
$ 39.3万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
10206705 - 财政年份:2016
- 资助金额:
$ 39.3万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
9750843 - 财政年份:2016
- 资助金额:
$ 39.3万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
10435488 - 财政年份:2016
- 资助金额:
$ 39.3万 - 项目类别:
Elucidating the Mechanisms Underlying Mutant TDP43-induced Neurodegeneration
阐明突变 TDP43 诱导的神经变性的机制
- 批准号:
8725311 - 财政年份:2011
- 资助金额:
$ 39.3万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 39.3万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 39.3万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 39.3万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 39.3万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 39.3万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 39.3万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 39.3万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 39.3万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 39.3万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 39.3万 - 项目类别:
Operating Grants














{{item.name}}会员




